HuidaGene Therapeutics’ Novel DNA Gene-Editing System Cas12i Patent Granted by USPTO
SHANGHAI and CLINTON, N.J., May 16, 2023 /PRNewswire/ — HuidaGene Therapeutics (辉大基因; HuidaGene), a clinical-stage company focusing on developing gene editing tools and gene therapies, today announced that the United States Patent and Trademark Office (USPTO) has granted to the Company patent US11,649,444B1 with respect to its independently-developed DNA editing system, CRISPR-Cas12i (Cas12Max®), in just 9 … Read more